Meeting Overview - The second meeting of the board of directors of Hubei Huqiang Technology Co., Ltd. was held on August 26, 2025, combining in-person and video conferencing [1] - The meeting was attended by all 9 directors, and it complied with relevant laws and regulations [1] Resolutions Passed - The board approved the 2025 semi-annual general manager's work report [2] - The board approved the 2025 semi-annual report and its summary [2] - The board approved the special report on the storage and actual use of raised funds for the first half of 2025 [2] - The board approved the risk assessment report regarding the financial liability company of the Equipment Group [2][3] - The board approved the proposal for asset impairment provisions for the first half of 2025 [3] - The board approved the proposal for the 2024 annual remuneration of management members [4] - The board approved the proposal to establish the Wuhan Advanced Materials Research Institute [4] - The board approved the mid-term adjustment of the 2025 investment plan [4] - The board approved the adjustment of the investment estimate for the first phase of the information technology construction project [4] - The board approved the organizational structure adjustment proposal [4] - The board approved the progress report of the 2025 "Quality Improvement and Efficiency Enhancement" special action plan [5]

Summary of Key Points Core Viewpoint - The company has announced the provision for asset impairment for the first half of 2025, reflecting a cautious approach to accurately represent its financial status as of June 30, 2025 [1][4]. Group 1: Impairment Provision Overview - The company conducted impairment testing on receivables and inventory to identify potential impairment signs as of June 30, 2025, resulting in a total impairment provision affecting current profit and loss amounting to -1,276,192.40 yuan [1][2]. - The total impact on the net profit attributable to the parent company is -30.88% for the first half of 2025 [2]. Group 2: Breakdown of Impairment Losses - The breakdown of credit impairment losses includes: - Notes receivable impairment loss: 170,949.60 yuan (4.14%) - Accounts receivable impairment loss: -1,137,355.31 yuan (-27.52%) - Other receivables impairment loss: -248,797.21 yuan (-6.02%) [2]. - The inventory impairment loss amounted to -60,989.48 yuan (-1.48%) [2]. Group 3: Accounting Methods - The company employs both aging group method and individual recognition method for bad debt provision: - Aging group method: 5% for under 1 year, 10% for 1-2 years, 30% for 2-3 years, 50% for 3-4 years, 80% for 4-5 years, and 100% for over 5 years [3]. - The inventory impairment provision is recognized when the cost exceeds the net realizable value [3]. Group 4: Impact and Compliance - The impairment provisions are in accordance with the Accounting Standards for Business Enterprises and reflect the company's actual situation, providing a fair representation of its financial condition [4][5]. - The board and supervisory committee have approved the impairment provision, confirming its compliance with relevant accounting standards and principles [4][5].

Core Points - The report details the fundraising and usage status of Hubei Huqiang Technology Co., Ltd. for the first half of 2025, ensuring compliance with regulatory requirements [1][5] - The total amount raised through the public offering was approximately RMB 3.02 billion, with a net amount of RMB 2.81 billion after deducting issuance costs [1][3] - As of June 30, 2025, the company has utilized RMB 1.51 billion of the raised funds, with a remaining balance of RMB 1.44 billion [1][4] Fundraising Overview - The company issued 86,206,200 shares at a price of RMB 35.09 per share, resulting in total fundraising of RMB 3,024,975,558.00 [1] - The funds were received on December 1, 2021, and have been audited by Da Xin Accounting Firm [1][2] Fund Usage - Cumulative usage of the raised funds as of June 30, 2025, was RMB 1,507,281,356.38, with RMB 264,318,264.54 used in the current year [1][4] - The remaining balance in the special account for the raised funds was RMB 1,435,171,906.68 [1][4] Fund Management - The company has established a management system for the raised funds, ensuring they are stored in a special account and used according to regulations [1][3] - A tripartite supervision agreement was signed with banks and the sponsor, ensuring compliance with fund management [1][3] Cash Management - The company has utilized part of the temporarily idle raised funds for cash management, with an amount of RMB 1,287,623,759.08 invested in structured deposits and other financial products [3][4] - The maximum amount for cash management is capped at RMB 2 billion, with a focus on low-risk financial products [3][4] Project Adjustments - The company has adjusted the implementation plans for several fundraising projects, including reducing the investment for the "New Nuclear Biological Emergency Rescue Protective Equipment Industrialization Production Base Project" from RMB 772 million to RMB 387.54 million [5][6] - New projects have been added, such as the "New Drug Delivery Device and Packaging Materials R&D and Industrialization Project," with a total investment of RMB 397.53 million [5][6] Compliance and Reporting - The company has confirmed that there are no discrepancies between the disclosed fundraising usage and the actual usage, ensuring timely and accurate reporting [5][6] - There are no instances of using raised funds for non-compliant purposes or for repaying bank loans [5][6]

Core Viewpoint - The financial company under the Weapon Equipment Group has been evaluated for its operational qualifications, business scope, and risk management, indicating a stable financial condition and effective internal controls [2][20]. Company Overview - The financial company is a non-bank financial institution with a registered capital of approximately RMB 304.25 million, with major shareholders including the Weapon Equipment Group and other entities [3][20]. - The business scope includes accepting deposits, providing loans, bill discounting, and various financial advisory services [3][20]. Internal Control and Governance - The financial company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring a balanced decision-making process [4][6]. - The board of directors and various committees, including the risk control and audit committees, oversee the company's operations and risk management [7][8][9]. Financial Performance - As of June 30, 2025, the financial company reported total assets of RMB 587.42 billion, customer deposits of RMB 477.67 billion, and a net profit of RMB 1.87 billion for the first half of 2025 [12][20]. Risk Management - The financial company maintains a capital adequacy ratio of 21.65%, exceeding the regulatory requirement of 10.5%, and a liquidity ratio of 69.49%, which is above the minimum threshold of 25% [13][20]. - Various risk management strategies are in place to address compliance, credit, liquidity, market, operational, and information technology risks [16][17][18]. Conclusion - The financial company operates within regulatory frameworks, demonstrating sound financial health, effective internal controls, and a robust risk management system, making it a stable entity in the financial sector [20].

Core Viewpoint - The company is actively implementing the "Quality Improvement and Efficiency Enhancement" initiative, focusing on enhancing core capabilities, expanding market presence, and improving product quality while maintaining a commitment to shareholder interests and social responsibility [1][2][3]. Group 1: Strengthening Core Capabilities - The company has focused on the special protection field, achieving significant order fulfillment exceeding annual budget in the first half of 2025 [1]. - The company participated in four bidding processes for special products and successfully secured contracts, ensuring timely delivery [1]. - A new quality management system is being established, with training and process design completed [1]. Group 2: Civil Product Development - New product sales, such as pen-type injector components, have significantly increased, leading to a 3.48 percentage point rise in gross margin for civil products [2]. - The company has signed strategic cooperation agreements with new clients and expanded foreign trade channels, resulting in a 5% year-on-year increase in exports [2]. - The company successfully activated the registration number for a new insulin pen component, achieving important regulatory approval [2]. Group 3: Technological Innovation - Research and development investment reached 16.3% of revenue, a 4.65 percentage point increase year-on-year [2]. - The company has applied for 20 patents, including 15 invention patents, and achieved a 91.94% completion rate for research project milestones [2]. - An innovation platform is being established, centered around a national-level enterprise technology center [2]. Group 4: Quality and Efficiency Improvement - The company has implemented 86 specific measures to enhance quality and efficiency, focusing on cost reduction and revenue increase [3]. - A total of 6,715 million yuan was generated in additional revenue through various initiatives in the first half of 2025 [3]. - The company achieved a comprehensive cost reduction of 15.27 million yuan [3]. Group 5: Reform and Development - The company has completed 93% of its planned 100 reform tasks, receiving high marks in reform assessments [4]. - The brand strength increased by 7% to 892, maintaining its position on the Chinese brand value evaluation list [4]. - Digital transformation initiatives are underway, including the intelligent transformation of production facilities [4]. Group 6: Corporate Governance - The company has established a modern corporate governance system, implementing new management and compliance policies [6]. - A total of 68 announcements were made in the first half of 2025, including annual and quarterly reports [7]. - The company’s ESG rating improved from "BB" to "A," reflecting excellence in environmental, social, and governance practices [7]. Group 7: Investor Relations - The company has enhanced communication with investors, holding performance briefings and engaging in various outreach activities [8]. - A cash dividend of 0.434 yuan per share was distributed, representing 90.07% of the net profit attributable to shareholders [8]. - The company has established a value management system to comply with regulatory requirements and improve market performance [9]. Group 8: Management Responsibility - The company emphasizes the responsibility of key personnel, enhancing their awareness of compliance and operational standards [10]. - Training sessions for management and key personnel have been conducted to improve their capabilities [10]. Group 9: Future Outlook - The company will continue to evaluate the implementation of the "Quality Improvement and Efficiency Enhancement" initiative and maintain transparency in its operations [11].

Core Viewpoint - Hubei Huaqiang Technology Co., Ltd. reported a significant decline in revenue and profit for the first half of 2025, primarily due to reduced demand in its main business segments, particularly in special protective equipment and pharmaceutical packaging [3][5][7]. Financial Performance - The company achieved operating revenue of 177.73 million yuan, a decrease of 25.98% compared to the same period last year [3]. - Total profit amounted to 2.88 million yuan, down 88.98% year-on-year [3]. - Net profit attributable to shareholders was 4.13 million yuan, representing an 84.49% decline [3]. - The net cash flow from operating activities was a negative 23.44 million yuan, although this was an improvement of 80.04% year-on-year [3]. Business Segments - The special protective equipment segment saw a revenue decline of 28.63%, attributed to the timing of military orders, with most deliveries expected in the fourth quarter [3][8]. - The pharmaceutical packaging and medical device segment experienced a 25.67% revenue decrease, mainly due to reduced demand for butyl rubber stoppers in the antibiotic and chemical drug sectors [3][5]. Industry Context - The defense budget for 2025 is projected at 178.47 billion yuan, reflecting a 7.2% increase, which may enhance demand for military equipment [5][8]. - The pharmaceutical packaging industry is expected to grow, with a market size of 143.96 billion yuan in 2024, showing a 14.4% year-on-year increase [5][6]. Innovation and Development - The company has established itself as a leader in the domestic butyl rubber stopper market, achieving significant milestones in smart manufacturing and product development [6][14]. - The company has a strong focus on R&D, with 135 technical personnel, accounting for 20.55% of the total workforce, and has filed 20 patent applications during the reporting period [12][18]. Strategic Initiatives - The company is actively pursuing international market expansion and has signed strategic cooperation agreements with over 40 new clients [8][9]. - It has implemented a "strong foundation and new expansion" strategy to enhance core competitiveness and adapt to market changes [9][10].

| 湖北华强科技股份有限公司2025 | 年半年度报告摘要 | | | | --- | --- | --- | --- | | 公司代码：688151 | 公司简称：华强科技 | | | | 湖北华强科技股份有限公司 | 湖北华强科技股份有限公司2025 年半年度报告摘要 | | | | 第一节 | 重要提示 | | | | 规划，投资者应当到上海证券交易所网站（www.sse.com.cn）网站仔细阅读半年度报告全文。 | | | | | 公司已在本报告中描述公司面临的风险，敬请查阅本报告"第三节 | | | 管理层讨论与分 | | 析"之"四、风 | | | | | 险因素"部分，请投资者注意投资风险。 | | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | 无 | | | | | □适用 √不适用 | | | | | 第二节 | 公司基本情况 | | | | 公司股票简况 | | | | | 公司股票简况 | | | | | 股票种类 | 股票上市交易所 股票简称 股票代码 | | 变更前股票简称 | | 上海证券交易所科 | | | | | ...

Meeting Overview - The second supervisory board meeting of Hubei Huqiang Technology Co., Ltd. was held on August 26, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Financial Reports - The supervisory board approved the 2025 semi-annual report, confirming that it accurately reflects the company's financial status and operational results for the first half of 2025, with no false statements or omissions [2]. - The board also approved the semi-annual special report on the storage and actual use of raised funds, stating that the company adhered to legal requirements and properly managed the funds without misusing them [2]. Risk Assessment - The supervisory board approved the risk assessment report on the financial company of the Equipment Group, indicating no significant risks in the company's financial services or management [3]. Asset Impairment - The board approved the proposal for the provision (reversal) of asset impairment, affirming that it complies with accounting standards and accurately reflects the company's financial information [3][5].

湖北华强科技股份有限公司 2025 年度"提质增效重回报"专项行动方案的 进展报告 根据上海证券交易所发布的《关于开展沪市公司"提质增效重回报"专项行 动的倡议》，湖北华强科技股份有限公司（以下简称"公司"）积极践行"以投资 者为本"上市公司发展理念，维护公司全体股东利益，切实履行社会责任，于 2025 年 4 月 24 日披露《湖北华强科技股份有限公司 2025 年度"提质增效重回 报"行动方案》。2025 年上半年，公司根据行动方案积极落实相关举措并认真评 估实施效果，现将行动方案半年度进展情况报告如下： 一、坚决履行强军首责，核心能力进一步提升 深入学习贯彻习近平强军思想和新时代军事战略方针，聚焦特种防护领域， 提升强军胜战能力，聚焦市场开拓、生产任务完成、科研项目落地，抓实抓细各 项具体工作。一是积极落实特品订单。2025 年上半年，主动拓展新渠道，全力 争取订单，超额完成特品订单落实，总金额超过年度预算。二是积极参与各军兵 种招标。公司及时对接各军兵种的招标意向，累计参与特品竞标 4 次，成功中标 2 次。三是抓实生产组织，备产特品订单。以合同确定的交付节点为目标，狠抓 生产计划落实，确保保质保量准 ...

湖北华强科技股份有限公司 关于对兵器装备集团财务有限责任公司的 风险评估报告 按照中国证券监督管理委员会《关于规范上市公司与企业集团财务公司业务 往来的通知》《上市公司信息披露管理办法》《上市公司监管指引第 8 号——上市 公司资金往来、对外担保的监管要求》以及《企业集团财务公司管理办法》的要 求，通过查验兵器装备集团财务有限责任公司（以下简称"财务公司"）《金融许 可证》《企业法人营业执照》等证件资料，并审阅财务公司包括资产负债表、利 润表、现金流量表等在内的定期财务报告，湖北华强科技股份有限公司（以下简 称"公司"或"本公司"）对财务公司的经营资质、业务和风险状况进行了评估， 具体情况报告如下： 一、财务公司基本情况 （一）业务资质 财务公司已按照《公司法》《企业集团财务公司管理办法》等相关规定和《兵 器装备集团财务有限责任公司章程》的公司治理制度建立了完善的公司治理架构， 并根据相关议事规则履行职责。同时，财务公司按照决策系统、执行系统、监督 反馈系统互相制衡的原则设置了公司组织架构。 1.财务公司的组织架构 1．财务公司是经国家金融监督管理总局（原中国银行保险监督管理委员会） 批准成立的非银行金融机构 ...